IMMUNO-ONCOLOGY INSIGHTS

Assessing the evolving I-O landscape: key challenges and opportunities for 2024

Assessing the evolving I-O landscape: key challenges and opportunities for 2024

Samik Upadhaya

Samik Upadhaya, Assistant Director, Scientific Affairs

Progress being made in solid tumors
Are cancer vaccines back from the dead?
What’s next for checkpoints?
- What will the development of biosimilars mean for the field?
Investor, financial, and market access trends

Combination therapy development

Combination therapy development

Are multimodality approaches the future of the field?
With combination trials proving complex and expensive, how can resources best be deployed/ trial design be optimized?
Combinations in solid tumors—opportunities and challenges
Safety considerations: will synergistic effect also result in synergistic toxicity?

Enhancing clinical development and patient stratification

Enhancing clinical development and patient stratification

Clinical trial design innovation and dose selection and optimization
Increasing global patient access and patient diversity
Improved methods of early detection and optimizing precision medicine strategies
Combining and integrating emerging tools to turn data to knowledge

Tools and trends of tomorrow

Tools and trends of tomorrow

What lessons can be drawn from previous negative outcomes from preclinical and clinical studies?
Does the field need to better manage toxicity with existing therapies, or find new targets and approaches?
Exploring key enabling technology and platform innovation trends and advances for the year(s) to come
Making models more applicable for safety and efficacy